{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:38:14Z","timestamp":1776940694824,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The science and technology innovation Program of Hunan Province","award":["2021RC2025"],"award-info":[{"award-number":["2021RC2025"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the abnormal vasculation and proliferation, the tumor microenvironment is hypoxic, lacking nutrients, and under high interstitial pressure. Compared to oxygen and nutrients, the effect of pressure on cancer biology remains poorly studied. Here we constructed \u03b1ROR1-CAR T cells and co-cultured with A549 cells with and without elevated pressure. We then measured apoptosis and cell death by flow cytometry and luciferase activity. We also measured cytokine (IL-2, IFN-\u03b3, and TNF-\u03b1) release by ELISA. The results show that pressure-preconditioned A549 cells are much resistant to \u03b1ROR1-CAR T cell-mediated cytotoxicity. Pressure preconditioning does not appear to affect the expression of \u03b1ROR1-CAR or cytokine production. However, pressure preconditioning upregulates PD-L1 expression in A549 cells and decreases cytokine release from \u03b1ROR1-CAR T cells. In addition, Pembrolizumab and Cemiplimab that block PD-1::PD-L1 interaction increase the cytokine production in \u03b1ROR1-CAR T cells, increase the apoptotic cell death in A549 cells, and improve the \u03b1ROR1-CAR T-mediated cytotoxicity. In xenograft mice, pressure preconditioning increases tumorigenesis of A549 cells, which can be blocked by a combined therapy using Pembrolizumab and \u03b1ROR1-CAR T cells. Together, our studies suggest that elevated pressure in the tumor microenvironment could blunt the T cell therapy by upregulating PD-L1 expression, which could be overcome by combining CAR T therapy with immune checkpoint inhibitors.<\/jats:p>","DOI":"10.1038\/s41598-022-10905-6","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T09:03:47Z","timestamp":1651136627000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity"],"prefix":"10.1038","volume":"12","author":[{"given":"Zhenglin","family":"Ou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Dou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"key":"10905_CR1","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.25418","volume":"94","author":"S Feins","year":"2019","unstructured":"Feins, S., Kong, W., Williams, E. F., Milone, M. C. & Fraietta, J. A. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am. J. Hematol. 94, S3\u2013S9. https:\/\/doi.org\/10.1002\/ajh.25418 (2019).","journal-title":"Am. J. Hematol."},{"key":"10905_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell https:\/\/doi.org\/10.1016\/j.ccell.2020.07.005 (2020).","journal-title":"Cancer Cell"},{"key":"10905_CR3","doi-asserted-by":"publisher","first-page":"3174","DOI":"10.1002\/eji.201242606","volume":"42","author":"M Aleksic","year":"2012","unstructured":"Aleksic, M. et al. Different affinity windows for virus and cancer-specific T-cell receptors: Implications for therapeutic strategies. Eur. J. Immunol. 42, 3174\u20133179. https:\/\/doi.org\/10.1002\/eji.201242606 (2012).","journal-title":"Eur. J. Immunol."},{"key":"10905_CR4","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","volume":"5","author":"C Zhang","year":"2017","unstructured":"Zhang, C., Liu, J., Zhong, J. F. & Zhang, X. Engineering CAR-T cells. Biomark. Res. 5, 22. https:\/\/doi.org\/10.1186\/s40364-017-0102-y (2017).","journal-title":"Biomark. Res."},{"key":"10905_CR5","doi-asserted-by":"publisher","first-page":"251513552092716","DOI":"10.1177\/2515135520927164","volume":"8","author":"L Halim","year":"2020","unstructured":"Halim, L. & Maher, J. CAR T-cell immunotherapy of B-cell malignancy: The story so far. Ther. Adv. Vaccines Immunother. 8, 2515135520927164. https:\/\/doi.org\/10.1177\/2515135520927164 (2020).","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"10905_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41389-017-0011-9","volume":"7","author":"V Petrova","year":"2018","unstructured":"Petrova, V., Annicchiarico-Petruzzelli, M., Melino, G. & Amelio, I. The hypoxic tumour microenvironment. Oncogenesis 7, 10. https:\/\/doi.org\/10.1038\/s41389-017-0011-9 (2018).","journal-title":"Oncogenesis"},{"key":"10905_CR7","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.55185","author":"AR Lim","year":"2020","unstructured":"Lim, A. R., Rathmell, W. K. & Rathmell, J. C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife https:\/\/doi.org\/10.7554\/eLife.55185 (2020).","journal-title":"Elife"},{"key":"10905_CR8","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1080\/14728222.2019.1702974","volume":"23","author":"LC Bockelmann","year":"2019","unstructured":"Bockelmann, L. C. & Schumacher, U. Targeting tumor interstitial fluid pressure: Will it yield novel successful therapies for solid tumors?. Expert Opin. Ther. Targets 23, 1005\u20131014. https:\/\/doi.org\/10.1080\/14728222.2019.1702974 (2019).","journal-title":"Expert Opin. Ther. Targets"},{"key":"10905_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/bjc.1994.89","volume":"69","author":"I Lee","year":"1994","unstructured":"Lee, I., Boucher, Y., Demhartner, T. J. & Jain, R. K. Changes in tumour blood flow, oxygenation and interstitial fluid pressure induced by pentoxifylline. Br. J. Cancer 69, 492\u2013496. https:\/\/doi.org\/10.1038\/bjc.1994.89 (1994).","journal-title":"Br. J. Cancer"},{"key":"10905_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s13139-019-00598-7","volume":"53","author":"HG Kim","year":"2019","unstructured":"Kim, H. G. et al. Measurement of tumor pressure and strategies of imaging tumor pressure for radioimmunotherapy. Nucl. Med. Mol. Imaging 53, 235\u2013241. https:\/\/doi.org\/10.1007\/s13139-019-00598-7 (2019).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"10905_CR11","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3892\/ijmm.2013.1496","volume":"32","author":"T Yu","year":"2013","unstructured":"Yu, T. et al. High interstitial fluid pressure promotes tumor cell proliferation and invasion in oral squamous cell carcinoma. Int. J. Mol. Med. 32, 1093\u20131100. https:\/\/doi.org\/10.3892\/ijmm.2013.1496 (2013).","journal-title":"Int. J. Mol. Med."},{"key":"10905_CR12","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nrc1456","volume":"4","author":"CH Heldin","year":"2004","unstructured":"Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure\u2014An obstacle in cancer therapy. Nat. Rev. Cancer 4, 806\u2013813. https:\/\/doi.org\/10.1038\/nrc1456 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"10905_CR13","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1152\/physiolgenomics.00182.2003","volume":"17","author":"P Yang","year":"2004","unstructured":"Yang, P. et al. DNA microarray analysis of gene expression in human optic nerve head astrocytes in response to hydrostatic pressure. Physiol. Genomics 17, 157\u2013169. https:\/\/doi.org\/10.1152\/physiolgenomics.00182.2003 (2004).","journal-title":"Physiol. Genomics"},{"key":"10905_CR14","first-page":"93","volume":"40","author":"HM Karjalainen","year":"2003","unstructured":"Karjalainen, H. M. et al. Gene expression profiles in chondrosarcoma cells subjected to cyclic stretching and hydrostatic pressure. A cDNA array study. Biorheology 40, 93\u2013100 (2003).","journal-title":"Biorheology"},{"key":"10905_CR15","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1158\/0008-5472.CAN-12-0903","volume":"72","author":"T Hompland","year":"2012","unstructured":"Hompland, T., Ellingsen, C., Ovrebo, K. M. & Rofstad, E. K. Interstitial fluid pressure and associated lymph node metastasis revealed in tumors by dynamic contrast-enhanced MRI. Cancer Res. 72, 4899\u20134908. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-0903 (2012).","journal-title":"Cancer Res."},{"key":"10905_CR16","doi-asserted-by":"publisher","first-page":"6201","DOI":"10.1158\/1078-0432.CCR-09-0560","volume":"15","author":"SG Yeo","year":"2009","unstructured":"Yeo, S. G., Kim, J. S., Cho, M. J., Kim, K. H. & Kim, J. S. Interstitial fluid pressure as a prognostic factor in cervical cancer following radiation therapy. Clin. Cancer Res. 15, 6201\u20136207. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-0560 (2009).","journal-title":"Clin. Cancer Res."},{"key":"10905_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1158\/1078-0432.CCR-09-2718","volume":"16","author":"EK Rofstad","year":"2010","unstructured":"Rofstad, E. K., Ruud, E. B., Mathiesen, B. & Galappathi, K. Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue. Clin. Cancer Res. 16, 936\u2013945. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-2718 (2010).","journal-title":"Clin. Cancer Res."},{"key":"10905_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2407-8-2","volume":"8","author":"SJ Lunt","year":"2008","unstructured":"Lunt, S. J. et al. Interstitial fluid pressure, vascularity and metastasis in ectopic, orthotopic and spontaneous tumours. BMC Cancer 8, 2. https:\/\/doi.org\/10.1186\/1471-2407-8-2 (2008).","journal-title":"BMC Cancer"},{"key":"10905_CR19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.tranon.2019.05.012","volume":"12","author":"LMK Hansem","year":"2019","unstructured":"Hansem, L. M. K. et al. Intratumor heterogeneity in interstitial fluid pressure in cervical and pancreatic carcinoma xenografts. Transl. Oncol. 12, 1079\u20131085. https:\/\/doi.org\/10.1016\/j.tranon.2019.05.012 (2019).","journal-title":"Transl. Oncol."},{"key":"10905_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1593\/neo.05469","volume":"8","author":"M Hofmann","year":"2006","unstructured":"Hofmann, M. et al. Lowering of tumor interstitial fluid pressure reduces tumor cell proliferation in a xenograft tumor model. Neoplasia 8, 89\u201395. https:\/\/doi.org\/10.1593\/neo.05469 (2006).","journal-title":"Neoplasia"},{"key":"10905_CR21","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1096\/fj.02-1201fje","volume":"17","author":"AV Salnikov","year":"2003","unstructured":"Salnikov, A. V. et al. Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy. FASEB J. 17, 1756\u20131758. https:\/\/doi.org\/10.1096\/fj.02-1201fje (2003).","journal-title":"FASEB J."},{"key":"10905_CR22","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1172\/JCI80011","volume":"125","author":"L Chen","year":"2015","unstructured":"Chen, L. & Han, X. Anti-PD-1\/PD-L1 therapy of human cancer: Past, present, and future. J. Clin. Investig. 125, 3384\u20133391. https:\/\/doi.org\/10.1172\/JCI80011 (2015).","journal-title":"J. Clin. Investig."},{"key":"10905_CR23","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab, H. O. et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front. Pharmacol. 8, 561. https:\/\/doi.org\/10.3389\/fphar.2017.00561 (2017).","journal-title":"Front. Pharmacol."},{"key":"10905_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/cr.2016.77","volume":"27","author":"Z Na","year":"2017","unstructured":"Na, Z. et al. Structural basis for blocking PD-1-mediated immune suppression by therapeutic antibody pembrolizumab. Cell Res. 27, 147\u2013150. https:\/\/doi.org\/10.1038\/cr.2016.77 (2017).","journal-title":"Cell Res."},{"key":"10905_CR25","doi-asserted-by":"publisher","first-page":"12568","DOI":"10.18632\/aging.102588","volume":"11","author":"C Lei","year":"2019","unstructured":"Lei, C. et al. Prognostic role of programmed death-ligand 1 expression in patients with biliary tract cancer: A meta-analysis. Aging (Albany NY) 11, 12568\u201312580. https:\/\/doi.org\/10.18632\/aging.102588 (2019).","journal-title":"Aging (Albany NY)"},{"key":"10905_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ejso.2015.01.020","volume":"41","author":"A Wang","year":"2015","unstructured":"Wang, A. et al. The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis. Eur. J. Surg. Oncol. 41, 450\u2013456. https:\/\/doi.org\/10.1016\/j.ejso.2015.01.020 (2015).","journal-title":"Eur. J. Surg. Oncol."},{"key":"10905_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316. https:\/\/doi.org\/10.1038\/bjc.2017.434 (2018).","journal-title":"Br. J. Cancer"},{"key":"10905_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang, X. et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol. Cancer 18, 10. https:\/\/doi.org\/10.1186\/s12943-018-0928-4 (2019).","journal-title":"Mol. Cancer"},{"key":"10905_CR29","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1158\/1078-0432.CCR-13-0330","volume":"19","author":"M Hudecek","year":"2013","unstructured":"Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153\u20133164. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0330 (2013).","journal-title":"Clin. Cancer Res."},{"key":"10905_CR30","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","volume":"23","author":"A Balakrishnan","year":"2017","unstructured":"Balakrishnan, A. et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin. Cancer Res. 23, 3061\u20133071. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2083 (2017).","journal-title":"Clin. Cancer Res."},{"key":"10905_CR31","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/j.ajpath.2012.08.024","volume":"181","author":"S Zhang","year":"2012","unstructured":"Zhang, S. et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am. J. Pathol. 181, 1903\u20131910. https:\/\/doi.org\/10.1016\/j.ajpath.2012.08.024 (2012).","journal-title":"Am. J. Pathol."},{"key":"10905_CR32","doi-asserted-by":"publisher","first-page":"793","DOI":"10.2217\/14796694.4.6.793","volume":"4","author":"SJ Lunt","year":"2008","unstructured":"Lunt, S. J., Fyles, A., Hill, R. P. & Milosevic, M. Interstitial fluid pressure in tumors: Therapeutic barrier and biomarker of angiogenesis. Future Oncol. 4, 793\u2013802. https:\/\/doi.org\/10.2217\/14796694.4.6.793 (2008).","journal-title":"Future Oncol."},{"key":"10905_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40425-017-0230-9","volume":"5","author":"I Scarfo","year":"2017","unstructured":"Scarfo, I. & Maus, M. V. Current approaches to increase CAR T cell potency in solid tumors: Targeting the tumor microenvironment. J. Immunother. Cancer 5, 28. https:\/\/doi.org\/10.1186\/s40425-017-0230-9 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"10905_CR34","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1161\/HYPERTENSIONAHA.116.07237","volume":"68","author":"HA Itani","year":"2016","unstructured":"Itani, H. A. et al. Activation of human T cells in hypertension: Studies of humanized mice and hypertensive humans. Hypertension 68, 123\u2013132. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.07237 (2016).","journal-title":"Hypertension"},{"key":"10905_CR35","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun, C., Mezzadra, R. & Schumacher, T. N. Regulation and function of the PD-L1 checkpoint. Immunity 48, 434\u2013452. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.014 (2018).","journal-title":"Immunity"},{"key":"10905_CR36","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.bbrc.2017.12.115","volume":"495","author":"A Miyazawa","year":"2018","unstructured":"Miyazawa, A. et al. Regulation of PD-L1 expression by matrix stiffness in lung cancer cells. Biochem. Biophys. Res. Commun. 495, 2344\u20132349. https:\/\/doi.org\/10.1016\/j.bbrc.2017.12.115 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10905_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2019.118526","volume":"1866","author":"S Azadi","year":"2019","unstructured":"Azadi, S. et al. Upregulation of PD-L1 expression in breast cancer cells through the formation of 3D multicellular cancer aggregates under different chemical and mechanical conditions. Biochim. Biophys. Acta Mol. Cell Res. 1866, 118526. https:\/\/doi.org\/10.1016\/j.bbamcr.2019.118526 (2019).","journal-title":"Biochim. Biophys. Acta Mol. Cell Res."},{"key":"10905_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011867","volume":"5","author":"X Fu","year":"2010","unstructured":"Fu, X. et al. A simple and sensitive method for measuring tumor-specific T cell cytotoxicity. PLoS\u00a0One 5, e11867. https:\/\/doi.org\/10.1371\/journal.pone.0011867 (2010).","journal-title":"PLoS\u00a0One"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10905-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10905-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10905-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T02:03:58Z","timestamp":1669341838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-10905-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["10905"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-10905-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6919"}}